Submission of Matters to a Vote of Security

The 2016 annual meeting of stockholders for Aytu BioScience, Inc. for the fiscal year ended June 30, 2016 was held on November 15, 2016. Of the 5,080,591 shares outstanding on the record date for the meeting, a total of 3,825,030 shares were present or represented at the meeting.

At the meeting, our stockholders elected five members to our board of directors as follows:

Members

Number of Shares Voted For

Number of

Shares Withheld

(Includes Abstentions)

Broker Non-Votes

Gary V. Cantrell

2,698,093

33,988

1,092,949

Joshua R. Disbrow

2,675,629

56,452

1,092,949

Carl C. Dockery

2,673,683

58,398

1,092,949

John A. Donofrio, Jr.

2,698,076

34,005

1,092,949

Michael Macaluso

2,673,427

58,654

1,092,949

The election of directors was determined by a plurality of the votes cast at the meeting, whereby the five nominees receiving the highest number of FOR votes were elected as directors.

At the meeting, our stockholders took the following actions:

Approved, by a majority of the shares of our outstanding capital stock, an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number between 1-for-2 and 1-for-4, as determined by the board of directors, at any time before November 15, 2017, if and as determined by the board of directors. The vote for such approval was 3,504,083 shares for, 310,053 shares against, 10,894 shares abstaining, and no shares of broker non-votes;

Approved, by a majority of the shares voting at the meeting, amendments to our 2015 Stock Option and Incentive Plan to (i) increase

the number of authorized shares of common stock reserved for issuance thereunder from 833,334 shares to 2,000,000 shares, (ii) increase the number of shares that may be issued as incentive stock options from 833,334 shares to 2,000,000 shares,

and (iii) increase the maximum number of shares of common stock (A) underlying stock options or stock appreciation rights that may be granted to any one individual during any calendar year period, and (B) granted to any one individual that is intended to qualify as performance-based compensation under Section162(m) of the Internal Revenue Code of 1986, as amended, for any performance cycle, in each case from 166,667 shares to 1,000,000 shares. The vote for such approval was 2,360,026 shares for, 370,957 shares against, 1,098 shares abstaining, and 1,092,949 shares of broker non-votes; and

Ratified, by a majority of the shares voting at the meeting, the appointment of EKS&H, LLLP as our independent registered public accounting firm for the fiscal year ending June 30, 2017. The vote for such approval was 3,757,747 shares for, 25,898 shares against, 41,385 shares abstaining, and no shares of broker non-votes.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 16, 2016

AYTU BIOSCIENCE, INC.

/s/ Gregory A. Gould

Name: Gregory A. Gould

Title: Chief Financial Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

General form for registration of securities under the Securities Act of 1933 - Sept. 25, 2017
General form for registration of securities under the Securities Act of 1933 - Sept. 22, 2017
General form for registration of securities under the Securities Act of 1933 - Sept. 5, 2017
Rosewind: Aytu Bioscience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update - Aug. 31, 2017
Rosewind CORP Just Filed Its Annual Report: Note 14 – Subsequ... - Aug. 31, 2017

Auto Refresh

Feedback